DEVELOP OF ANTIBODY FRAGM AS CONTR AGT FOR MRI OF ALZH?S DIS AMYLOID PLAQUES

开发抗体片段作为 ALZH 淀粉样斑块 MRI 的对照 AGT

• 批准号: 8170473
• 负责人: MICHAEL GARWOOD
• 金额: $ 2.57万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8170473
• 关键词: Alzheimer' s Disease; Amyloid; Antibodies; Blood; Brain; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Diagnostic; Early Diagnosis; Funding; Grant; Human; Image; Institution; Lead; Magnetic Resonance; Measures; Modification; Monoclonal Antibodies; Nerve; Nervous system structure; Proteins; Research; Research Personnel; Resources; Senile Plaques; Source; Testing; Transgenic Mice; United States National Institutes of Health; in vivo; molecular imaging; therapeutic target

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ability to target therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain/nerve barriers. In this project we are testing the hypothesis that modifications of an F(ab2)2 fragment of a monoclonal antibody (IgG4.1) against fibrillar human A¿42 can be used for the molecular imaging of amyloid plaques in Alzheimer's disease (AD) using high field strength magnetic resonance microimaging (MRMI) (9.4 T). The ability of this contrast agent to image plaques in vivo in AD transgenic mice may lead to early diagnosis of AD in humans and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 受血脑/神经屏障的存在限制了将治疗或诊断蛋白靶向治疗或诊断蛋白的能力。在这个项目中，我们正在测试以下假设：F（AB2）2单克隆抗体（IgG4.1）对原纤维人类Aa§42的修饰（IgG4.1）可用于使用高场强度磁共振磁共振成像（AD）中的淀粉样蛋白（AD）的分子成像。这种对比剂在AD转基因小鼠体内成像体内形象斑块的能力可能会导致人类的AD早期诊断，并且还可以直接测量目前正在开发的抗淀粉样疗法的效率。